Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Julie Renee Brahmer, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · The Lancet Oncology · 2017

Cited by 348 works. doi:10.1016/s1470-2045(17)30690-3

Authors

References